Lung cancer can now be prevented with a vaccine.

Lung cancer can now be prevented with a vaccine.

 

Humanity is embarking on a campaign to conquer lung cancer, the world's leading cause of cancer death. Utilizing messenger ribonucleic acid (mRNA) technology, which enabled the development of the COVID-19 vaccine, the development of a lung cancer vaccine has begun, with the first clinical trials already underway in seven countries, including the US and the UK. With Yuhan Corporation's lung cancer treatment "Leclaza" receiving approval from the US Food and Drug Administration (FDA), expectations for lung cancer treatment are rising, and attention is focused on whether humanity will gain a new weapon in its fight against the disease.

 

According to the UK's National Institute for Health Research (UCLH) on the 27th, clinical trials for the mRNA-based lung cancer vaccine "BNT116," developed by German biotechnology company BioNTech, recently began. Beginning with the first patient receiving the vaccine candidate in the UK today, the trial is scheduled to proceed at 34 institutions in seven countries. This marks the first clinical trial of an mRNA vaccine targeting lung cancer in the world.

This vaccine is based on mRNA. mRNA-based cancer vaccines, a key enabler of the rapid development of COVID-19 vaccines, induce the body to produce abnormal proteins produced by cancer cells. This in turn triggers the body's immune cells to produce antibodies in response. These antibodies then kill the cancer cells.

It's estimated that 1.8 million people worldwide die from lung cancer each year. Even with treatment, recurrence and metastasis are common. Preventing recurrence is essential to increasing the survival rate of lung cancer patients.

BNT116 is a vaccine that prevents relapse. It strengthens the body's immune response to cancer cells, significantly reducing the risk of metastasis or relapse. Unlike chemotherapy, it also has the advantage of not affecting healthy cells.

 

The clinical trial will involve 130 subjects, including patients with early-stage, advanced, or recurrent lung cancer. They will receive the vaccine for six consecutive weeks, followed by three weekly doses over a 54-week period.

 

[Reporter Go Jae-won]

 

 

=========================

 

Lung cancer is a silent disease.

I was wondering if I might get lung cancer when I had my health checkup this year.

I'm trying to get it checked

 

That's good news

 

If a vaccine is available... even if it costs your life

It will decrease